Country: Malta
Language: English
Source: Medicines Authority
ETODOLAC
2care4 Generics ApS Stenhuggervej 12-14, 6710 Esbjerg V, Denmark
M01AB08
ETODOLAC 200 mg
FILM-COATED TABLET
ETODOLAC 200 mg
POM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
Withdrawn
2013-05-30
Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER ETODOLAC 2CARE4 200 MG FILM-COATED TABLETS ETODOLAC 2CARE4 300 MG FILM-COATED TABLETS ETODOLAC READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Etodolac 2care4 is and what it is used for 2. What you need to know before you take Etodolac 2care4 3. How to take Etodolac 2care4 4. Possible side effects 5. How to store Etodolac 2care4 6. Contents of the pack and other information 1. WHAT ETODOLAC 2CARE4 IS AND WHAT IT IS USED FOR Etodolac 2care4 is a pain-killing and anti-inflammatory agent. It belongs to the group of non steroid anti-inflammatory drugs (NSAIDs). You can take Etodolac 2care4 • For the treatment of rheumatic diseases • For the treatment of pain and swelling of joints and muscles Your doctor may have given you Etodolac 2care4 for a different disorder. Always follow your doctor's orders. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ETODOLAC 2CARE4 DO NOT TAKE ETODOLAC 2CARE4 • if you are allergic to etodolac or any of the other ingredients of this medicine (listed in section 6); • if you have experienced bleeding from your stomach or intestines or your intestines have been perforated due to treatment with painkillers (NSAIDs); • if you have or have had gastric ulcer or gastric bleeding more than once; • if you have a very bad liver or kidneys; • if you have a very bad heart; • if you have a low platelet count in your blood; • if you have previously had difficulty in breathing, asthma, hives or a cold after treatm Read the complete document
Page 1 of 10 SUMMARY OF PRODUCT CHARACTERISTICS ETODOLAC 2CARE4 200MG FILM-COATED TABLETS ETODOLAC 2CARE4 300MG FILM-COATED TABLETS 1. NAME OF THE MEDICINAL PRODUCT Etodolac 2care4 200mg film-coated tablets Etodolac 2care4 300mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200mg of etodolac Each tablet contains 300mg of etodolac Excipient(s) with known effect: Each tablet contains 85 mg lactose monohydrate and 15mg sodium starch glycolate. Each tablet contains 127.5 mg lactose monohydrate and 22.5mg sodium starch glycolate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Rheumatic diseases and other inflammatory disorders. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Symptoms should be treated at the lowest effective dose for the least amount of time to minimize adverse reactions of Etodolac 2care4 (see section 4.4). ADULTS 200mg twice daily, if necessary increased to 200mg three times daily or 300mg twice daily. OLDER PEOPLE Elderly patients often experience adverse reactions following the use of NSAIDs, see section The treatment should be initiated at the lowest effective dose. _Paediatric population_ Etodolac 2care4 should not be used in children. The safety and efficacy of etodolac in children have not been established. IMPAIRED RENAL FUNCTION Caution should be exercised in patients with impaired renal function, see section 4.4. Page 2 of 10 Method of administration For oral administration The tablets must be taken with a glass of water. 4.3 CONTRAINDICATIONS Etodolac 2care4 is contraindicated in: • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. • A history of gastrointestinal bleeding or perforation in connection with NSAID treatment. • Active or recurrent gastrointestinal ulcer or gastrointestinal bleeding (i.e. two or several individual episodes of diagnosed ulcer or bleeding). • Severe hepatic or renal failure ( Read the complete document